X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Following closing of the Transaction, Orgenesis plans to accelerate the commercial scaleup of KYSLECEL throughout the United States and, subject to regulatory and logistical considerations, in international markets as well.
Lead Product(s): Autologous pancreatic islets cells
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Kyslecel
Highest Development Status: ApprovedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Orgenesis
Deal Size: $16.3 million Upfront Cash: Undisclosed
Deal Type: Acquisition September 29, 2020
Details:
KT-PC-301 is a cell therapy that is derived from a patient’s own adipose (fat) tissue. The planned phase 2 trial will enroll 75 patients and evaluate the safety and efficacy of KT-PC-301 as compared to placebo.
Lead Product(s): KT-PC-301
Therapeutic Area: Infections and Infectious Diseases Product Name: KT-PC-301
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 21, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
